Rimegepant
Menstrual Migraine
PfizerSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Menstrual Migraine cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Treximet® Cady, Roger, M.D. | Phase 4 | BB |
Fremanezumab Insel Gruppe AG, University Hospital Bern | Phase 4 | BB |
3.BETA.-HYDROXY-5.ALPHA.-TETRAHYDROPROGESTERONE Asarina Pharma | Phase 2 | B |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Saglik Bilimleri Universitesi | N/A | D |
Same molecule, other indications
Rimegepant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →